HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $912 | +14.6% | 23,869 | +8.2% | 0.01% | +25.0% |
| Q2 2023 | $796 | -92.3% | 22,069 | -91.9% | 0.00% | -93.3% |
| Q1 2023 | $10,390 | +783.5% | 272,069 | +1216.3% | 0.06% | +757.1% |
| Q4 2022 | $1,176 | -99.9% | 20,669 | 0.0% | 0.01% | +40.0% |
| Q3 2022 | $817,000 | -10.1% | 20,669 | 0.0% | 0.01% | -16.7% |
| Q2 2022 | $909,000 | -3.3% | 20,669 | -12.3% | 0.01% | +20.0% |
| Q1 2022 | $940,000 | -17.9% | 23,569 | -17.2% | 0.01% | -16.7% |
| Q4 2021 | $1,145,000 | -1.1% | 28,469 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $1,158,000 | -10.4% | 28,469 | 0.0% | 0.01% | -14.3% |
| Q2 2021 | $1,293,000 | +32.2% | 28,469 | +21.3% | 0.01% | +16.7% |
| Q1 2021 | $978,000 | -25.1% | 23,469 | -23.2% | 0.01% | -25.0% |
| Q4 2020 | $1,306,000 | +21.9% | 30,569 | -25.0% | 0.01% | 0.0% |
| Q3 2020 | $1,071,000 | -51.0% | 40,769 | -50.0% | 0.01% | -11.1% |
| Q2 2020 | $2,186,000 | – | 81,538 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |